 |
|
PGC-1 Expression Decreases in the Alzheimer Disease Brain as a Function of Dementia
Weiping Qin, MD, PhD;
Vahram Haroutunian, PhD;
Pavel Katsel, PhD;
Christopher P. Cardozo, MD;
Lap Ho, PhD;
Joseph D. Buxbaum, PhD;
Giulio M. Pasinetti, MD, PhD
Arch Neurol. 2009;66(3):352-361.
ABSTRACT
Objectives To explore mechanisms through which altered peroxisome proliferator–activated receptor  coactivator 1 (PGC-1) expression may influence Alzheimer disease (AD) amyloid neuropathology and to test the hypothesis that promotion of PGC-1 expression in neurons might be developed as a novel therapeutic strategy in AD.
Design Case-control.
Patients Human postmortem brain (hippocampal formation) samples from AD cases and age-matched non-AD cases.
Results Using genome-wide complementary DNA microarray analysis, we found that PGC-1 messenger RNA expression was significantly decreased as a function of progression of clinical dementia in the AD brain. Following confirmatory real-time polymerase chain reaction assay, we continued to explore the role of PGC-1 in clinical dementia and found that PGC-1 protein content was negatively associated with both AD-type neuritic plaque pathology and β-amyloid (Aβ)X-42 contents. Moreover, we found that the predicted elevation of amyloidogenic Aβ1-42 and Aβ1-40 peptide accumulation in embryonic cortico-hippocampal neurons derived from Tg2576 AD mice under hyperglycemic conditions (glucose level, 182-273 mg/dL) coincided with a dose-dependent attenuation in PGC-1 expression. Most importantly, we found that the reconstitution of exogenous PGC-1 expression in Tg2576 neurons attenuated the hyperglycemic-mediated β-amyloidogenesis through mechanisms involving the promotion of the "nonamyloidogenic" -secretase processing of amyloid precursor protein through the attenuation of the forkheadlike transcription factor 1 (FoxO3a) expression.
Conclusion Therapeutic preservation of neuronal PGC-1 expression promotes the nonamyloidogenic processing of amyloid precursor protein precluding the generation of amyloidogenic Aβ peptides.
INTRODUCTION
Alzheimer disease (AD) is a neurodegenerative disorder of the central nervous system. The neuropathological hallmarks of AD include extracellular amyloid-containing plaques and intracellular neurofibrillary tangles.1 The molecular events leading to the development of sporadic late-onset AD have not been defined. Advanced age is the largest AD risk factor and glucose/energy metabolism is decreased during aging.2-7 Recent evidence strongly supports the hypothesis that type 2 diabetes mellitus (T2D) is also a risk factor for AD.8-11 Moreover, recent evidence suggests that worsening in cerebral glucose metabolism is associated with progression of AD clinical dementia.12-16
Positron emission tomography studies demonstrated that glucose use is reduced markedly in the brain of mild cognitive impairment and early-stage AD.4-5,17-23 In contrast to controls, glucose ingestion significantly elevated hippocampal glucose concentrations in persons with AD, suggesting that cerebral glucose hypometabolism in AD results in increased steady-state concentrations of cerebral glucose.24 This evidence strongly associates brain glucose hypometabolic conditions and possibly T2D with the onset and progression of AD.
The present study was designed to explore mechanisms through which altered expression of peroxisome proliferator–activated receptor (PPAR-) coactivator 1 (PGC-1), a key regulator of glucose homeostasis in the liver and muscle during fasting or in conditions of insulin resistance in T2D through the activation of gluconeogenic metabolic pathways,25-33 may influence AD amyloid neuropathology and to test the hypothesis that promotion of PGC-1 expression in neurons might be developed as a novel therapeutic strategy in AD.
METHODS
POSTMORTEM AD BRAIN FOR THE CHARACTERIZATION OF PGC-1 EXPRESSION IN THE AD BRAIN
Human postmortem brain (hippocampal formation) samples from AD cases and age-matched non-AD cases were obtained from the Alzheimer's Disease Brain Bank of the Mount Sinai School of Medicine. The precise tissue handling procedures have been described in detail previously (eTable 1).34-38
MICROARRAY PROCEDURE
The procedures used for microarray analysis of gene expression in human hippocampal formation have been published previously (eTable 1).39-44
CONFIRMATORY REAL-TIME POLYMERASE CHAIN REACTION STUDIES
RNA was quantified by absorbance at 260/280 nm. One microgram of total RNA was used to prepare complementary DNA (cDNA) libraries using the High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, California) in a total volume of 20 µL. Data were normalized relative to those for neuron-specific enolase RNA (or glyceraldehyde-3-phosphate dehydrogenase [GAPDH] RNA) (eFigure). Levels of PGC-1 or forkheadlike transcription factor (FoxO) 3a messenger RNA (mRNA) were expressed relative to those in control groups using the 2- Ct method.45
CONFIRMATORY WESTERN BLOT ANALYSIS
Aliquots of crushed, never-thawed hippocampal formation tissue were extracted in phosphate-buffered saline containing final concentrations of 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and 0.1mM edetic acid plus protease inhibitors. Antibodies used include PGC-1 (H-300, 1:500 dilution; Santa Cruz Biotechnology, Inc, Santa Cruz, California); anti-FKHRL-1 (FoxO3a) (1:1000 dilution; Upstate Biotechnology, Inc, Lake Placid, New York); polyclonal anti–amyloid precursor protein (APP) C terminal (751-770) antibody (anti-O443, 1:5000 dilution; Calbiochem, San Diego, California); monoclonal 6E10 antibody (1:1000 dilution; Senetek, St Louis, Missouri); and monoclonal 22C11 antibody (1:1000 dilution; Senetek). In this study, β-actin immunoreactivity (1:1000 dilution; Sigma, St Louis) controlled for selectivity of changes. NIH/3T3+platelet-derived growth factor cell lysate (Santa Cruz Biotechnology) and DU145 nuclear extract (Santa Cruz Biotechnology) were used to assess specificity of detection in FoxO3a and PGC-1 immunoreactivity, respectively.
QUANTIFICATION OF β-AMYLOIDX-42 PEPTIDE CONTENT IN THE HUMAN BRAIN
For the β-amyloid (Aβ) peptide assay, hippocampal formation frozen brain tissue samples were first pulverized in dry ice and cortical Aβx-42 was extracted and quantified as previously described.46
TISSUE CELL CULTURES
Embryonic (E14) cortico-hippocampal primary neuronal cultures derived from Tg2576 transgenic mice (Tg2576 neurons) were prepared as previously described.47 To study the effect of glucose on amyloidogenesis, culture medium was replaced with Dulbecco modified Eagle medium in the presence of the desired concentration of glucose (91 mg/dL for normoglycemia condition and 182-273 mg/dL for hyperglycemia condition [to convert to millimoles per liter, multiply by 0.055]). For adenoviral infection studies, Tg2576 neuronal (5-day-old) (18 hours after plating) cultures were infected with PGC-1,31 constitutively active (CA) FoxO3a,48 or green fluorescent protein (GFP) control adenoviruses at doses defined as multiplicities of infection (MOI).
QUANTIFICATION OF Aβ PEPTIDES IN THE CONDITIONED MEDIUM IN PRIMARY NEURON CULTURES
The quantitative assessment of Aβ peptides in primary cortico-hippocampal neuron cultures derived from embryonic Tg2576 mice was performed by enzyme-linked immunosorbent assays as previously described.49-50
FLUORIMETRIC ASSESSMENT OF APP SECRETASE ACTIVITIES
-, β-, and -Secretase activities were assessed using commercially available kits (R&D Systems, Minneapolis, Minnesota) as previously described.51-54
STATISTICAL ANALYSIS
Analysis of variance (ANOVA) was used to evaluate differences in mean values among 3 or more groups, and the Dunnett t test was used to test the significance of differences between group pairs. One-tailed or 2-tailed tests were used as indicated. Correlation analysis between 2 variables was done using the Pearson parametric method followed by 2-way analysis of P value.
RESULTS
IDENTIFICATION OF GENE PRODUCTS INVOLVED IN METABOLIC FUNCTIONS WHOSE EXPRESSION IS CHANGED AS A FUNCTION OF PROGRESSION OF CLINICAL AD DEMENTIA
To clarify the molecular mechanisms involved in onset and progression of AD dementia, we used DNA microarray assays to identify candidate genes, the expression of which is altered in the AD brain at different stages of clinical dementia and neuropathology relative to controls without dementia. Among others, we report that we found a strong association between the altered expression of a series of gene products involved in glucose metabolism as well as in mitochondrial oxidative phosphorylation in the hippocampal formation of the AD brain. eTable 2 shows the alteration in gene expression involved in glucose metabolism and oxidative phosphorylation we found across all of the analyzed regions as a function of Clinical Dementia Rating (CDR). We report the association between the decreased expression of PGC-1 in the AD brain as a function of progression of clinical dementia and AD neuropathology.
CONFIRMATORY EVIDENCE THAT HIPPOCAMPAL PGC-1 EXPRESSION IS DECREASED AS A FUNCTION OF AD CLINICAL DEMENTIA
The decreased expression in PGC-1 mRNA and eventually in PGC-1 protein content in the hippocampal formation of AD cases as a function of clinical dementia assessed by CDR was confirmed by quantitative real-time polymerase chain reaction normalizing with GAPDH mRNA (eFigure A) and Western blot analysis (Figure 1B) (P < .001; R2 = 0.8331; 1-way ANOVA), respectively. To exclude the possibility that the decrease in PGC-1 mRNA expression (Figure 1A) may be secondary to neuronal and synaptic loss that also correlates strongly with clinical dementia, we normalized PGC-1 mRNA expression with a different neuronal specific "housekeeping" gene, neuron-specific enolase, and found that alteration of PGC-1 mRNA expression as a function of clinical dementia remained the same (Figure 1A) (P = .001; R2 = 0.3992; 1-way ANOVA).
|
|
|
Figure 1. Hippocampal peroxisome proliferator–activated receptor coactivator 1 (PGC-1) expression in the Alzheimer disease (AD) brain decreases as a function of AD dementia and AD β-amyloid (Aβ) neuropathology. A, PGC-1 messenger RNA (mRNA) content in the hippocampal formation (quantified by real-time reverse transcriptase–polymerase chain reaction and normalized by neuron-specific enolase [NSE]) as a function of Clinical Dementia Rating (CDR) representing cognitive normalcy (CDR = 0), questionable dementia (CDR = 0.5), mild dementia (CDR = 2), and severe dementia (CDR = 5). B, Western blot confirmation of decreased PGC-1 protein content in the hippocampal formation of AD cases. In A and B, data represent mean (SEM) and are shown as a percentage relative to the CDR = 0 group. *P < .05,  P < .003, and  P < .01 vs control group by t test. C and D, PGC-1 mRNA expression as a function of Aβ neuritic plaque neuropathology in accord with the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) 4-point scale (n = 4, 4, 3, and 3 for CERAD scores of 0, 1, 3, and 5, respectively) for AD (C) or content of Aβx-42 (n = 12) (D). Straight line represents best linear regression fit.
|
|
|
Relative to cases with normal cognitive status (CDR = 0), the level of hippocampal PGC-1 protein and mRNA expression was significantly decreased in cases characterized by moderate dementia (CDR = 2) and severe dementia (CDR = 5) (P < .05 and P < .003, respectively) (Figure 1A and B and eTable 1). No detectable change in PGC-1 attenuation was found in cases at high risk to develop AD (mild cognitive impairment) (CDR = 0.5) (Figure 1A and B).
DECREASED EXPRESSION OF HIPPOCAMPAL PGC-1 PROTEIN CONTENT CORRELATES WITH PROGRESSION OF AMYLOID NEUROPATHOLOGY IN AD
We found that the decreased PGC-1 protein content in the hippocampal formation of the cases examined correlated with the density of neuritic plaque (P < .05; r2 = 0.673; P < .001; n = 14) (Figure 1C).
To further explore the functional relationship between the changes in hippocampal PGC-1 expression and amyloid neuropathology, we explored the relationship between PGC-1 protein content and Aβ peptide content in the brain of AD cases. We found that the hippocampal PGC-1 protein content inversely correlated with total Aβx-42 content in the EC-BM36/38 (Pearson correlation coefficient r2 = –0.411; P = .02; n = 12). This association tentatively suggests that a decrease in PGC-1 expression in the AD brain might be associated with conditions promoting AD Aβ amyloidogenesis.
HYPERGLYCEMIA-MEDIATED ATTENUATION OF PGC-1 EXPRESSION IN Tg2576 NEURONS COINCIDES WITH INCREASED Aβ PEPTIDE CONTENT IN THE CONDITIONED MEDIUM
We treated Tg2576 neurons with increasing glucose concentrations from 91 to 273 mg/dL in the culture-conditioned medium to match extracellular concentrations of glucose found in either normoglycemic (glucose concentration, 91 mg/dL) or hyperglycemic T2D conditions (glucose concentration, 182-273 mg/dL) in humans.32-33 We found that hyperglycemic conditions resulted in a significant decrease in PGC-1 protein content in the Tg2576 neurons in a dose-dependent manner (182 mg/dL, P < .05 and 273 mg/dL, P < .01), relative to control Tg2576 neurons cultured in normoglycemic conditions, 24 hours after treatment (Figure 2A).
The decreased PGC-1 protein content in Tg2576 neurons coincided with a significant dose-dependent elevation in endogenous Aβ1-40 and Aβ1-42 peptide contents in the Tg2576 neuron culture medium (182 mg/dL, P < .05 and 273 mg/dL, P < .01), relative to control Tg2576 neurons cultured in normoglycemic conditions, 24 hours after treatment (Figure 2B).
EXOGENOUS VIRAL EXPRESSION OF PGC-1 PREVENTS HYPERGLYCEMIA-MEDIATED POTENTIATION OF Aβ PEPTIDE ACCUMULATION IN THE CONDITIONED MEDIUM IN Tg2576 NEURONS
To further explore the role of PGC-1 in the promotion of Aβ peptide content in vitro, we tested the hypothesis that exogenous expression of PGC-1 in Tg2576 neurons might attenuate hyperglycemia-mediated accumulation of Aβ1-40 and Aβ1-42 content toward levels found in Tg2576 neurons cultured in control normoglycemic conditions.
We found that exogenous adenoviral expression (10 MOI) of PGC-131 resulted in approximately a 2- to 3-fold elevation in PGC-1 protein content in the Tg2576 neuron cultures, relative to control normoglycemic GFP adenoviral–expressing Tg2576 neurons (Figure 2C). Exogenous expression of PGC-1 significantly reduced the hyperglycemic-mediated attenuation of PGC-1 protein expression in Tg2576 neurons (Figure 2C), which coincided with a significant attenuation of Aβ1-40 and Aβ1-42 peptide content in the Tg2576 culture medium toward levels found in Tg2576 neurons cultured in control normoglycemic conditions, 24 hours after infection (Figure 2D). We also found that exogenous adenoviral expression of PGC-1 in Tg2576 neurons resulted in a moderate but significant decreased Aβ1-40 and Aβ1-42 peptide content in the culture medium relative to control normoglycemic GFP adenoviral–expressing Tg2576 neurons (Figure 2D).
HYPERGLYCEMIC CULTURE CONDITIONS SELECTIVELY ATTENUATE -SECRETASE ACTIVITY IN Tg2576 NEURONS
We found a selective attenuation of - (P < .05), but not β- or -, secretase activity (Figure 3A) in GFP-expressing Tg2576 neurons cultured in hyperglycemic conditions for 24 hours, which coincided with a commensurate attenuation of 6E10 immunoreactive soluble APP- (sAPP) content in the culture-conditioned medium (P < .05), relative to Tg2576 neurons cultured in normoglycemic conditions (Figure 3A and B).
EXOGENOUS PGC-1 EXPRESSION PREVENTS HYPERGLYCEMIC-MEDIATED ATTENUATION OF NONAMYLOIDOGENIC -SECRETASE PROCESSING OF APP IN Tg2576 NEURONS
Exogenous adenoviral PGC-1 expression in Tg2576 neurons cultured in normoglycemic conditions resulted in a selective elevation of - (P < .05), but not β- or -, secretase activity (Figure 3A) coincidental with a significant increase in sAPP content in the culture-conditioned medium (Figure 3B) (P < .005) relative to control GFP-expressing Tg2576 neurons cultured in normoglycemic conditions. Most importantly, we found that reconstitution of PGC-1 expression in Tg2576 neurons through exogenous adenoviral infection significantly prevented the hyperglycemic-mediated attenuation of -secretase activity (Figure 3A) 24 hours after exogenous viral infection.
These changes occurred in the absence of detectable variations in the content of 22C11 immunoreactive (total) sAPP in the conditioned medium (Figure 3A) or in O-443 immunoreactive full-length APP in Tg2576 neurons (Figure 3C), excluding the possibility that exogenous adenoviral PGF-1 expression influenced total APP expression.
This evidence indicates that exogenous neuronal expression of PGC-1 might therapeutically reverse hyperglycemia-mediated attenuation of the nonamyloidogenic -secretase processing of APP and diminish Aβ generation. The cerebral glucose hypometabolism reported in AD may result in increased steady-state levels of glucose in the brain20 that, through attenuation of PGC-1 expression, might exacerbate AD Aβ amyloidogenesis.
PGC-1 EXPRESSION PROMOTES NONAMYLOIDOGENIC PROCESSING OF APP THROUGH ATTENUATION OF EXPRESSION OF THE FoxO3a TRANSCRIPTION FACTOR
Recent evidence supports the hypothesis that PGC-1 may influence muscle atrophy, in part through suppression of FoxO3a.55 Moreover, we recently found that exogenous expression of FoxO3a (10 MOI)48 in Tg2576 neurons may causally promote AD-type Aβ levels through mechanisms that attenuate nonamyloidogenic -secretase processing of APP, suggesting an intrinsic association between FoxO3a activity and AD-type Aβ amyloidogensis.56
We found a significant elevation in FoxO3a protein content (P < .05) in GFP-expressing Tg2576 neurons cultured in hyperglycemic conditions relative to Tg2576 neurons cultured in normoglycemic conditions (Figure 4A) 24 hours after treatment. Most importantly, we found that exogenous adenoviral expression of PGC-1 significantly prevented the hyperglycemic-mediated potentiation of FoxO3a protein expression in Tg2576 neurons (Figure 4A) 24 hours after PGC-1 adenoviral infection.
We infected Tg2576 neurons with adenovirus-expressing CA FoxO3a or GFP control vector in combination with viral PGC-1 or control GFP infection in a culture-conditioned medium with 91 mg/dL of glucose. As expected, we found that Tg2576 neurons expressing exogenous viral PGC-1 resulted in a significant elevation of sAPP content (P < .05) in the culture-conditioned medium 24 hours after infection relative to control GFP-infected cells (P < .05) (Figure 4B).
Moreover, we found that exogenous CA FoxO3a (10 MOI) expression in Tg2576 neurons significantly prevented PGC-1–mediated elevation of sAPP (Figure 4B), relative to control GFP (and PGC-1)-expressing Tg2576 neurons, in the absence of detectable changes in total sAPP in the conditioned medium (Figure 4B) or full-length cellular APP content (data not shown) 24 hours after infection.
Similarly, consistent with our previous findings,56 we found a significant diminution of sAPP (P < .05) in the culture-conditioned medium of Tg2576 neurons virally expressing CA FoxO3a, but not PGC-1, relative to control GFP-expressing Tg2576 neurons, further supporting the hypothesis of a direct inhibitory role of FoxO3a on the nonamyloidogenic -secretase processing of APP (Figure 4B).
Collectively, this finding strongly supports the hypothesis that the transcription factor FoxO3a may be a downstream effector of PGC-1 and supports the hypothesis that decreased PGC-1 expression in the AD brain might result in increased FoxO3a expression in the brain eventually promoting AD Aβ amyloidogenesis.
PGC-1 EXPRESSION INVERSELY CORRELATES WITH FoxO3a EXPRESSION IN THE AD BRAIN AS A FUNCTION OF PROGRESSION OF CLINICAL DEMENTIA
To further investigate the clinical relevance of the in vitro finding suggesting that FoxO3a may be involved in PGC-1–mediated AD Aβ amyloidogenesis, we continued to explore the regulation of the FoxO3a mRNA and protein contents in the brain of AD cases relative to neurological control cases and the association of FoxO3a expression with PGC-1 and AD Aβ neuropathology.
We found that FoxO3a mRNA expression and FoxO3a protein contents in the hippocampal formation were significantly increased in the AD brain as a function of CDR, as assessed by quantitative real-time polymerase chain reaction (Figure 5A and eFigure B) (P = .001; R2 = 0.5416; 1-way ANOVA) and Western blot analysis (Figure 5B) (P = .008; R2 = 0.4528; 1-way ANOVA), respectively.
|
|
|
|
Figure 5. Peroxisome proliferator–activated receptor coactivator 1 (PGC-1) expression inversely correlates with forkheadlike transcription factor 1 (FoxO3a) expression in the Alzheimer disease (AD) brain as a function of progression of clinical dementia. A, Forkheadlike transcription factor 1 messenger RNA (mRNA) content in hippocampal formation (quantified by real-time reverse transcriptase–polymerase chain reaction and normalized by neuron-specific enolase [NSE]) as a function of Clinical Dementia Rating (CDR). B, Western blot confirmation of increased FoxO3a protein contents in the hippocampal formation of AD cases. *P < .01, P < .003, and P < .05 vs control group by t test. C-E, Scatterplot analysis of FoxO3a protein expression (n = 13) as a function of PGC-1 expression (C), Consortium to Establish a Registry for Alzheimer's Disease (CERAD) 4-point scale (n = 3, 4, 2, and 3 for CERAD scores of 0, 1, 3, and 5, respectively) for AD (D), or for content of β-amyloid (Aβ)x-42 (n = 12) in the brain of AD cases (E). Straight line represents best linear regression fit.
|
|
|
Moreover, we found a strong inverse association between PGC-1 and FoxO3a protein content in the same postmortem brain tissue (Pearson correlation coefficient, r2 = –0.786; P < .001) (Figure 5C). Most importantly, we found that the increased in hippocampal FoxO3a protein content as a function of AD clinical dementia strongly associated with the increased density of neuritic plaques (Pearson correlation coefficient, r2 = 0.0001; P < .001) (Figure 5D). Finally, we found that the hippocampal FoxO3a protein content directly associated with total Aβx-42 content in the EC-BM36/38 (Pearson correlation coefficient, r2 = –0.411; P = .02) (Figure 5E), consistent with the hypothesis that decreased PGC-1 expression might causally promote AD Aβ amyloidogenesis through FoxO3a-mediated responses.
COMMENT
We report for the first time, to our knowledge, that PGC-1 expression is decreased in the brain of persons with AD as a function of dementia severity. Moreover, we found that experimental hyperglycemic conditions in cortico-hippocampal neuron cultures derived from Tg2576 embryos may significantly inhibit PGC-1 expression coincident with the elevation of Aβ peptide generation through a mechanism(s) involving the inactivation of nonamyloidogenic -secretase processing of APP.56-58 Finally, the cause-effect relationship between PGC-1 and Aβ peptide generation was confirmed by the demonstration that exogenous viral expression of PGC-1 in primary Tg2576 cortico-hippocampal neurons reverse glucose-mediated induction of amyloidogenic Aβ peptide accumulation in the conditioned medium.
Previous studies from our laboratory found that that inhibition of FoxO3a activity by calorie restriction results in improved glucose use and promotes nonamyloidogenic-mediated -secretase processing of APP precluding Aβ generation.56 Interestingly, in this study, we found that hyperglycemic conditions in vitro result in elevation of PGC-1–dependent FoxO3a expression coincident with inhibition of nonamyloidogenic processing of APP and promotion of Aβ generation in Tg2576 neurons.
It was hypothesized that a close relationship exists among PGC-1 function, insulin sensitivity, and T2D, which is most likely related to the essential role of PGC-1 in mitochondria biogenesis and glucose/fatty acid metabolism. In this context, thiazolidinediones, an important class of antidiabetic drugs and agonists of PPAR- currently being developed for the treatment of AD, also act to increase insulin sensitivity coincident with the activation of PPAR-.59 The effects of thiazolidinediones are likely mediated through the ability of PGC-1 to activate mitochondria biogenesis and increase mitochondrial function and eventually improve energy metabolism. Moreover, recent evidence suggests that activation of SIRT1, an oxidized nicotinamide adenine dinucleotide–dependent deacetylase and a principal modulator of pathways downstream of calorie restriction that we found to prevent AD-type Aβ amyloidogenesis in Tg2576 mice,50 may also protect against experimental T2D conditions through inhibition of PGC-1 acetylation and promotion of PGC-1 activity.60
We hypothesize that impaired glucose/energy metabolism and increased steady-state concentration of cerebral glucose in the AD brain, as demonstrated by previous studies,24 lead to attenuation of PGC-1 expression resulting in activation of FoxO3a expression, thereby inhibiting nonamyloidogenic -secretase processing of APP and increased generation of amyloidogenic Aβ peptides (Figure 6). The data suggest that cerebral glucose hypometabolism in AD may lead to an increased steady-state concentration of cerebral glucose as found in the AD brain,24 leading to alteration of PGC-1–mediated multiple-cellular functions that ultimately result in AD amyloid neuropathology.
AUTHOR INFORMATION
Correspondence: Giulio M. Pasinetti, MD, PhD, Departments of Psychiatry and Neuroscience, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1230, New York, NY 10029 (giulio.pasinetti{at}mssm.edu; for technical information, weiping.qin{at}mssm.edu).
Accepted for Publication: November 25, 2008.
Author Contributions: Study concept and design: Qin, Haroutunian, Ho, and Pasinetti. Acquisition of data: Qin and Katsel. Analysis and interpretation of data: Qin, Katsel, Cardozo, Buxbaum, and Pasinetti. Drafting of the manuscript: Qin, Ho, and Pasinetti. Critical revision of the manuscript for important intellectual content: Qin, Haroutunian, Katsel, Cardozo, Ho, Buxbaum, and Pasinetti. Statistical analysis: Qin and Pasinetti. Obtained funding: Qin. Administrative, technical, and material support: Qin, Haroutunian, Katsel, Cardozo, Ho, Buxbaum, and Pasinetti. Study supervision: Qin and Pasinetti.
Financial Disclosure: None reported.
Funding/Support: These studies were supported by the Dr Robert C. Atkins Foundation, National Institutes of Health grant AG14766, the Dana Foundation for Brain Research Initiative, Merit Review (Dr Pasinetti), and grant B4162C from the Department of Veterans Affairs Rehabilitation Research and Development Service.
Author Affiliations: Departments of Psychiatry (Drs Qin, Haroutunian, Katsel, Ho, Buxbaum, and Pasinetti), Medicine (Dr Cardozo), and Neuroscience (Drs Ho, Buxbaum, and Pasinetti), Mount Sinai School of Medicine, New York, and Geriatric Research Education and Clinical Center (Drs Ho and Pasinetti), James J. Peters VA Medical Center (Drs Ho and Pasinetti), Bronx, New York.
REFERENCES
1. Roberson ED, Mucke L. 100 Years and counting: prospects for defeating Alzheimer's disease. Science. 2006;314(5800):781-784.
FREE FULL TEXT
2. Frölich L, Blum-Degen D, Bernstein HG; et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm. 1998;105(4-5):423-438.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
3. Gerozissis K, Rouch C, Lemierre S, Nicolaidis S, Orosco M. A potential role of central insulin in learning and memory related to feeding. Cell Mol Neurobiol. 2001;21(4):389-401.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
4. Jagust WJ, Seab JP, Huesman RH; et al. Diminished glucose transport in Alzheimer's disease: dynamic PET studies. J Cereb Blood Flow Metab. 1991;11(2):323-330.
WEB OF SCIENCE
| PUBMED
5. Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr. 1995;19(4):541-547.
WEB OF SCIENCE
| PUBMED
6. Hoyer S. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp Gerontol. 2000;35(9-10):1363-1372.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
7. Hoyer S. Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv Exp Med Biol. 2004;541:135-152.
WEB OF SCIENCE
| PUBMED
8. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res. 2007;4(2):147-152.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
9. Craft S. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging. 2005;26(1)(suppl 1):65-69.
FULL TEXT
| PUBMED
10. Awad N, Gagnon M, Messier C. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol. 2004;26(8):1044-1080.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
11. Craft S, Newcomer J, Kanne S; et al. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging. 1996;17(1):123-130.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
12. Hoyer S. Abnormalities of glucose metabolism in Alzheimer's disease. Ann N Y Acad Sci. 1991;640:53-58.
PUBMED
13. Fukuyama H, Ogawa M, Yamauchi H; et al. Altered cerebral energy metabolism in Alzheimer's disease: a PET study. J Nucl Med. 1994;35(1):1-6.
FREE FULL TEXT
14. Mielke R, Herholz K, Grond M, Kessler J, Heiss WD. Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type. Neurobiol Aging. 1992;13(1):93-98.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
15. Herholz K, Schopphoff H, Schmidt M; et al. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. J Nucl Med. 2002;43(1):21-26.
FREE FULL TEXT
16. Henneberg N, Hoyer S. Desensitization of the neuronal insulin receptor: a new approach in the etiopathogenesis of late-onset sporadic dementia of the Alzheimer type (SDAT)? Arch Gerontol Geriatr. 1995;21(1):63-74.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
17. de Leon MJ, Ferris SH, George AE; et al. Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer's disease. J Cereb Blood Flow Metab. 1983;3(3):391-394.
WEB OF SCIENCE
| PUBMED
18. Smith GS, de Leon MJ, George AE; et al. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease: pathophysiologic implications. Arch Neurol. 1992;49(11):1142-1150.
FREE FULL TEXT
19. Hoyer S. Intermediary metabolism disturbance in AD/SDAT and its relation to molecular events. Prog Neuropsychopharmacol Biol Psychiatry. 1993;17(2):199-228.
FULL TEXT
| PUBMED
20. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol. 2004;490(1-3):115-125.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
21. Small GW, Ercoli LM, Silverman DH; et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97(11):6037-6042.
FREE FULL TEXT
22. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A. 2001;98(6):3334-3339.
FREE FULL TEXT
23. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry. 2002;159(5):738-745.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
24. Haley AP, Knight-Scott J, Simnad VI, Manning CA. Increased glucose concentration in the hippocampus in early Alzheimer's disease following oral glucose ingestion. Magn Reson Imaging. 2006;24(6):715-720.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
25. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev. 2003;24(1):78-90.
FREE FULL TEXT
26. Yoon JC, Puigserver P, Chen G; et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature. 2001;413(6852):131-138.
FULL TEXT
| PUBMED
27. Herzig S, Long F, Jhala US; et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature. 2001;413(6852):179-183.
FULL TEXT
| PUBMED
28. Puigserver P, Rhee J, Donovan J; et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature. 2003;423(6939):550-555.
FULL TEXT
| PUBMED
29. Rhee J, Inoue Y, Yoon JC; et al. Regulation of hepatic fasting response by PPAR coactivator-1 (PGC-1): requirement for hepatocyte nuclear factor 4 in gluconeogenesis. Proc Natl Acad Sci U S A. 2003;100(7):4012-4017.
FREE FULL TEXT
30. Lin J, Wu PH, Tarr PT; et al. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1 null mice. Cell. 2004;119(1):121-135.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
31. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 2005;434(7029):113-118.
FULL TEXT
| PUBMED
32. Liang H, Ward WF. PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ. 2006;30(4):145-151.
FREE FULL TEXT
33. Tomlinson DR, Gardiner NJ. Glucose neurotoxicity. Nat Rev Neurosci. 2008;9(1):36-45.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
34. Haroutunian V, Perl DP, Purohit DP; et al. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol. 1998;55(9):1185-1191.
FREE FULL TEXT
35. Davis KL, Mohs RC, Marin D; et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 1999;281(15):1401-1406.
FREE FULL TEXT
36. Haroutunian V, Purohit DP, Perl DP; et al. Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch Neurol. 1999;56(6):713-718.
FREE FULL TEXT
37. Haroutunian V, Davies PJ, Vianna C, Buxbaum JD, Purohit DP. Tau protein abnormalities associated with the progression of Alzheimer disease type dementia. Neurobiol Aging. 2007;28(1):1-7.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
38. Mirra SS, Heyman A, McKeel D; et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41(4):479-486.
FREE FULL TEXT
39. Katsel P, Davis KL, Haroutunian V. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophr Res. 2005;79(2-3):157-173.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
40. Katsel P, Davis KL, Gorman JM, Haroutunian V. Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophr Res. 2005;77(2-3):241-252.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
41. Katsel P, Li C, Haroutunian V. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? Neurochem Res. 2007;32(4-5):845-856.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
42. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19(2):185-193.
FREE FULL TEXT
43. Irizarry RA, Hobbs B, Collin F; et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-264.
ABSTRACT
44. Klipper-Aurbach Y, Wasserman M, Braunspiegel-Weintrob N; et al. Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med Hypotheses. 1995;45(5):486-490.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
45. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402-408.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
46. Näslund J, Haroutunian V, Mohs R; et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000;283(12):1571-1577.
FREE FULL TEXT
47. Kelley KA, Ho L, Winger D; et al. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am J Pathol. 1999;155(3):995-1004.
WEB OF SCIENCE
| PUBMED
48. Skurk C, Maatz H, Kim HS; et al. The Akt-regulated forkhead transcription factor FoxO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J Biol Chem. 2004;279(2):1513-1525.
FREE FULL TEXT
49. Qin W, Ho L, Pompl PN; et al. Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity. J Biol Chem. 2003;278(51):50970-50977.
FREE FULL TEXT
50. Qin W, Yang T, Ho L; et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem. 2006;281(31):21745-21754.
FREE FULL TEXT
51. Burns M, Gaynor K, Olm V; et al. Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. J Neurosci. 2003;23(13):5645-5649.
FREE FULL TEXT
52. Rezai-Zadeh K, Shytle D, Sun N; et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci. 2005;25(38):8807-8814.
FREE FULL TEXT
53. Wang J, Ho L, Qin WP; et al. Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J. 2005;19(6):659-661.
FREE FULL TEXT
54. Qin W, Chachich M, Lane M; et al. Calorie restriction attenuates Alzheimer's disease type brain amyloidosis in Squirrel monkeys (Saimiri sciureus). J Alzheimers Dis. 2006;10(4):417-422.
WEB OF SCIENCE
| PUBMED
55. Sandri M, Lin J, Handschin C; et al. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U S A. 2006;103(44):16260-16265.
FREE FULL TEXT
56. Qin W, Zhao W, Ho L; et al. Regulation of forkhead transcription factor FoxO3a contributes to calorie restriction-induced prevention of Alzheimer's disease-type amyloid neuropathology and spatial memory deterioration. Ann N Y Acad Sci. 2008;1147:335-347.
WEB OF SCIENCE
| PUBMED
57. Gandy S. Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer's disease. Neurobiol Aging. 2002;23(6):1009-1016.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
58. Selkoe DJ. Amyloid β-protein and the genetics of Alzheimer's disease. J Biol Chem. 1996;271(31):18295-18298.
FREE FULL TEXT
59. Landreth G. PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease. Exp Neurol. 2006;199(2):245-248.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
60. Lagouge M, Argmann C, Gerhart-Hines Z; et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127(6):1109-1122.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Chronic caloric restriction attenuates a loss of sulfatide content in PGC-1{alpha} mouse cortex: a potential lipidomic role of PGC-1{alpha} in neurodegeneration
Kiebish et al.
J. Lipid Res. 2012;53:273-281.
ABSTRACT
| FULL TEXT
Sustained expression of PGC-1{alpha} in the rat nigrostriatal system selectively impairs dopaminergic function
Ciron et al.
Hum Mol Genet 2012;0:ddr618v2-ddr618.
ABSTRACT
| FULL TEXT
Mitochondrial Parkin Recruitment Is Impaired in Neurons Derived from Mutant PINK1 Induced Pluripotent Stem Cells
Seibler et al.
J. Neurosci. 2011;31:5970-5976.
ABSTRACT
| FULL TEXT
Parvalbumin Deficiency and GABAergic Dysfunction in Mice Lacking PGC-1{alpha}
Lucas et al.
J. Neurosci. 2010;30:7227-7235.
ABSTRACT
| FULL TEXT
|
